Barclays Maintains Overweight on Immunogen, Raises Price Target to $27
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Peter Lawson maintains an Overweight rating on Immunogen (NASDAQ:IMGN) and raises the price target from $20 to $27.
August 04, 2023 | 10:50 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays maintains an Overweight rating on Immunogen and raises the price target from $20 to $27, which could lead to a positive market reaction.
The raised price target by Barclays indicates a positive outlook for Immunogen. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100